Amy Moskop, New ACT Lead for CIBMTR

It gives us great pleasure to announce that Amy Moskop, MD, MS, has been confirmed as the new co-Principal Investigator (PI) on U24-CA076518: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research. In this role, she will partner with Bronwen Shaw, MD, PhD, on this multiple PI grant and will lead the adoptive cellular therapy (ACT) research agenda scope of the award.

Since joining CIBMTR as a faculty member, Dr. Moskop has been dedicated to the advancement of the ACT agenda and a key person on first the Cellular Immunotherapy Data Resource (CIDR) and then U24 resource grants. Over this time, she has taken on significant leadership roles, including being named CIBMTR’s Scientific Director for gene therapy, leading the Working Committee scope of studies in the ACT portfolio, and driving research on subsequent neoplasms post chimeric antigen receptor T-cell (CAR-T) therapy.

In her new role, Dr. Moskop will take on leadership of the ACT Stakeholder’s Council, represent the ACT scope to CIBMTR’s Advisory Committee, and lead the continued growth and development of this important scope of work within CIBMTR. CIBMTR is grateful to Dr. Moskop for her significant and ongoing contributions and her enthusiasm and drive to achieve our mission to improve patient outcomes. Please join us in congratulating her.